Literature DB >> 17140253

Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.

Florencia Anatelli1, Pawel Mroz, Qingde Liu, Changming Yang, Ana P Castano, Emilia Swietlik, Michael R Hamblin.   

Abstract

A conjugate between maleylated albumin and a photosensitizer (PS) shows cell type specific targeting to macrophages via the scavenger receptor. Administration of this conjugate to a tumor-bearing mouse followed by illumination may allow selective destruction of macrophages within tumors. There is accumulating evidence that tumor-associated macrophages contribute to tumor growth, invasiveness, metastasis, and immune suppression. We tested the intravenous (IV) injection of a conjugate between maleylated albumin and chlorin(e6) to BALB/c mice bearing three tumor types with differing proportions of tumor-associated macrophages. The accumulation of PS within the tumors after IV injection and 24 h incubation time was disappointing, and we therefore investigated intratumoral (IT) injection. This gave 20-50 times greater concentrations of PS within the tumor compared to IV injection as determined by tissue extraction. Furthermore the amounts of PS in each tumor type correlated well with the numbers of macrophages both as determined by extraction from bulk tumor and fluorescence quantification and as determined by tissue dissociation to a single cell suspension and two-color flow cytometry with macrophage-specific antibodies. IT injection of nonconjugated PS gave lower tumor accumulation that did not correlate with macrophage content. IT injection of targeted macromolecular delivery systems is an underexplored area and worthy of further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17140253      PMCID: PMC2504868          DOI: 10.1021/mp060024y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  44 in total

Review 1.  Targeted photodynamic therapy via receptor mediated delivery systems.

Authors:  Wesley M Sharman; Johan E van Lier; Cynthia M Allen
Journal:  Adv Drug Deliv Rev       Date:  2004-01-13       Impact factor: 15.470

2.  Tumor-associated macrophages as targets for cancer therapy.

Authors:  L M Wahl; H K Kleinman
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

3.  Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1.

Authors:  J H Harmey; E Dimitriadis; E Kay; H P Redmond; D Bouchier-Hayes
Journal:  Ann Surg Oncol       Date:  1998 Apr-May       Impact factor: 5.344

4.  Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer.

Authors:  M R Hamblin; J L Miller; I Rizvi; B Ortel; E V Maytin; T Hasan
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

5.  Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft.

Authors:  P E Kristjansen; Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

6.  Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice.

Authors:  A Mantovani; R Giavazzi; N Polentarutti; F Spreafico; S Garattini
Journal:  Int J Cancer       Date:  1980-05-15       Impact factor: 7.396

Review 7.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

8.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.

Authors:  Tove Olafsen; Giselle J Tan; Chia-Wei Cheung; Paul J Yazaki; Jinha M Park; John E Shively; Lawrence E Williams; Andrew A Raubitschek; Michael F Press; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2004-06-08       Impact factor: 1.650

9.  Establishment of mouse colonic carcinoma cell lines with different metastatic properties.

Authors:  M G Brattain; J Strobel-Stevens; D Fine; M Webb; A M Sarrif
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

10.  On the source of the oscillations observed during in vivo zinc phthalocyanine fluorescence pharmacokinetic measurements in mice.

Authors:  E F Gudgin Dickson; H Holmes; G Jori; J C Kennedy; P Nadeau; R H Pottier; F Rossi; D A Russell; G E Weagle
Journal:  Photochem Photobiol       Date:  1995-05       Impact factor: 3.421

View more
  5 in total

1.  The impact of macrophage-cancer cell interaction on the efficacy of photodynamic therapy.

Authors:  Mladen Korbelik; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-01-26       Impact factor: 3.982

2.  Intravascular detection of inflamed atherosclerotic plaques using a fluorescent photosensitizer targeted to the scavenger receptor.

Authors:  Ahmed Tawakol; Ana P Castano; Faten Gad; Touqir Zahra; Gregory Bashian; Raymond Q Migrino; Atosa Ahmadi; Jeremy Stern; Florencia Anatelli; Stephanie Chirico; Azadeh Shirazi; Sakeenah Syed; Alan J Fischman; James E Muller; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2007-10-29       Impact factor: 3.982

3.  Glycolaldehyde and maleyl conjugated human serum albumin as potential macrophage-targeting carriers for molecular imaging purposes.

Authors:  Björn Gustafsson; Ulf Hedin; Kenneth Caidahl
Journal:  Contrast Media Mol Imaging       Date:  2014-04-22       Impact factor: 3.161

4.  A novel tumor targeting drug carrier for optical imaging and therapy.

Authors:  Rui Li; Ke Zheng; Ping Hu; Zhuo Chen; Shanyong Zhou; Jincan Chen; Cai Yuan; Song Chen; Wei Zheng; En Ma; Fengling Zhang; Jinping Xue; Xueyuan Chen; Mingdong Huang
Journal:  Theranostics       Date:  2014-03-24       Impact factor: 11.556

Review 5.  Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives.

Authors:  Yamin Yang; Yue Hu; Hongjun Wang
Journal:  Oxid Med Cell Longev       Date:  2016-09-08       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.